Thalassemia Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Thalassemia is a blood disorder that is characterized by abnormal production of hemoglobin in an affected person. It is a hereditary disorder inherited from parents. Patients with insufficient hemoglobin also suffer from thalassemia. Thalassemia is caused by abnormality or mutation in one or more genes responsible for the production of hemoglobin. When a person acquires from only one affected gene from the parents then the person becomes a carrier of thalassemia. Because thalassemia is a hereditary disorder; one of the parents must be a bearer for thalassemia. When both the parents are the bearers then the chances of giving birth to a thalassemia affected infant is quite high. Thalassemia is usually of two categories: alpha thalassemia and beta thalassemia.

MARKET DYNAMICS

Thalassemia market is driving due to factors such increasing prevalence of thalassemia and increase in awareness about available treatment options. However, factor such as the high cost of the treatment is expected to hamper the market growth.

MARKET SCOPE

The Thalassemia market analysis to 2031 is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Thalassemia Market with detailed market segmentation by treatment type, disease type and end user. The Thalassemia Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Thalassemia market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Thalassemia market is segmented on the basis of treatment type, disease type and end user. Based on treatment type, market is segmented as blood transfusions, iron chelation therapy, folic acid supplements, bone marrow transplants. Based on disease type, market is segmented as alpha thalassemia, beta thalassemia. Based on end user, market is segmented as hospitals, research institutes, diagnostic laboratories.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Thalassemia market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Thalassemia market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Thalassemia market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Thalassemia market in these regions.

MARKET PLAYERS

The report covers key developments in the Thalassemia market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as Application and End user launches, Application and End user approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Thalassemia market are anticipated to have lucrative growth opportunities in the future with the rising demand for Thalassemia in the global market. Below mentioned is the list of few companies engaged in the Thalassemia Market.

The report also includes the profiles of key players in Thalassemia market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•   Bluebird Bio, Inc.
  
•   Acceleron Pharma, Inc.
  
•   GlaxoSmithKline plc.
  
•   La Jolla Pharmaceutical Company
  
•   Incyte Corporation
  
•   IONIS Pharmaceuticals
  
•   Kiadis Pharma
  
•   Sangamo Bioscience
  
•   Lonza Group Ltd.
  
•   Celgene Corporation
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Thalassemia Report Scope